Physician profile
Aliya Haider
NPI 1114152303
$2,571.38
in general payments reported to CMS, 2019-2025
25 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $270 · 2021: $130 · 2022: $175 · 2023: $179 · 2024: $346 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.79 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $372.48 | 2019-2025 | |
| Viiv Healthcare Company | $356.66 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $344.46 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Paratek Pharmaceuticals, INC. | $220.83 | 2019-2025 | Nuzyra |
| Insmed, INC. | $201.49 | 2019-2025 | Arikayce |
| Shionogi INC | $178.31 | 2022-2025 | Fetroja |
| Astellas Pharma US INC | $139.17 | 2019-2024 | Veozah |
| Cumberland Pharmaceuticals, INC. | $139.14 | 2025 | Vibativ |
| Pfizer INC. | $102.42 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $83.47 | 2023-2025 | Vowst |
| Abbvie INC. | $69.12 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $40.37 | 2019 | |
| Theratechnologies INC. | $37.42 | 2019 | |
| Melinta Therapeutics, LLC | $36.31 | 2019 | |
| Nabriva Therapeutics, Plc | $34.96 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $33.16 | 2019-2023 | Heplisav-B |
| Janssen Products, LP | $29.99 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $28.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.92 | 2022 | |
| La Jolla Pharmaceutical Company | $18.32 | 2024 | Xerava |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Novo Nordisk INC | $15.68 | 2023 | |
| Janssen Biotech, INC. | $13.64 | 2023 | Symtuza |
| Amgen INC. | $12.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliya Haider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.